Literature DB >> 31283007

Identification of TAF1, SAT1, and ARHGEF9 as DNA methylation biomarkers for hepatocellular carcinoma.

Chudong Cai1, Xiaojun Xie2, Junyi Zhou1, Xi Fang1, Fang Wang3, Meng Wang4.   

Abstract

Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. More than 90% of primary HCC is HCC. Hepatitis C virus (HCV) infection and alcohol consumption have been widely accepted as two major risk factors for developing HCC. Herein, we aimed to identify DNA methylation genes related to both HCV infection and alcohol consumption. In this study, we identified methylation genes that were associated with the risk of HCV infection and alcohol consumption, respectively, by a large-scale bioinformatic analysis. Through PPI network analysis, we revealed the associations between the two types of genes and found six hub genes-TAF1, SAT1, Phospholipase C-beta 2, FGD1, ARHGAP4, and ARHGEF9-that may be associated with both HCV infection and alcohol consumption. Gene Ontology enrichment analysis was used to analyze the function which these genes in the network enriched. Among them, TAF1, SAT1, and ARHGEF9 were methylated genes that have been found to be related to tumor progression in HCC patients. Through independent data sets, we verified the methylation pattern of these six genes in HCC samples that had both HCV infection and alcohol consumption risks. Furthermore, we found that three of the six methylated genes were also associated with the prognosis of HCC patients. To summarize, we identified six hub genes that were associated with both HCV infection and alcohol consumption in the progress of HCC. The six methylation genes that might play an important role in both HCV infection and alcohol consumption would be potential therapy targets for HCC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  alcohol consumption; hepatitis C virus infection; hepatocellular carcinoma; methylation

Year:  2019        PMID: 31283007     DOI: 10.1002/jcp.28999

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  Analysis of ARHGAP4 Expression With Colorectal Cancer Clinical Characteristics and Prognosis.

Authors:  Ming-Sheng Fu; Shu-Xian Pan; Xun-Quan Cai; Yuan-Xin Hu; Wei-Jie Zhang; Qin-Cong Pan
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting PI3K/AKT signaling pathway.

Authors:  Zehao Niu; Yan Li; Yujian Xu; Weiqian Jiang; Ran Tao; Youbai Chen; Yan Han
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  ARHGEF3 regulates the stability of ACLY to promote the proliferation of lung cancer.

Authors:  Feifei Zhou; Wenqian Ai; Yixing Zhang; Qifan Hu; Mingxi Gan; Jian-Bin Wang; Tianyu Han
Journal:  Cell Death Dis       Date:  2022-10-14       Impact factor: 9.685

4.  A methylation-driven gene panel predicts survival in patients with colon cancer.

Authors:  Yaojun Peng; Jing Zhao; Fan Yin; Gaowa Sharen; Qiyan Wu; Qi Chen; Xiaoxuan Sun; Juan Yang; Huan Wang; Dong Zhang
Journal:  FEBS Open Bio       Date:  2021-07-28       Impact factor: 2.693

5.  Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.

Authors:  Yanhong Shang; Xiaofang Li; Weiwei Liu; Xiaoliang Shi; Shaohua Yuan; Ran Huo; Guotao Fang; Xiao Han; Jingnan Zhang; Kunjie Wang; Zhengyue Dou; Yan Zhang; Aimin Zang; Lin Zhang
Journal:  Sci Rep       Date:  2020-11-20       Impact factor: 4.379

6.  Hypermethylation of the PZP gene is associated with hepatocellular carcinoma cell proliferation, invasion and migration.

Authors:  Minhua Wu; Hui Lan; Zhongwei Ye; Yonghui Wang
Journal:  FEBS Open Bio       Date:  2021-02-21       Impact factor: 2.693

7.  Hypomethylation-Mediated AGR2 Overexpression Facilitates Cell Proliferation, Migration, and Invasion of Lung Adenocarcinoma.

Authors:  Junming He; Yin Fu; Jiangwei Hu; Jian Chen; Guoliang Lou
Journal:  Cancer Manag Res       Date:  2021-06-30       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.